A Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1

This was a Phase I, multi-centered, open-label, non-comparative dose-finding study to evaluate the safety, tolerability, and PK of DTG when added to standard ARV prophylaxis in singleton full-term (≥ 37 weeks gestation at birth) infants born to mothers living with HIV-1, and to propose an appropriate DTG dosing regimen during the first four weeks of life for infants born to mothers living with HIV-1. The infant and mother were enrolled as a pair, with the mother taken off study after completing the Entry visit and the infant followed through the Week 16 visit (Days 112-140 of life). Infants were enrolled in two sequential dosing cohorts: Cohort 1 (two single DTG doses) and Cohort 2 (chronic DTG dosing through a Week 4 or 6 visit per local standard of care for ARV prophylaxis). Cohort 1 was intended to generate the PK and safety data that would inform DTG dose selection for Cohort 2. At study entry in both cohorts, the participants were stratified based on the infant's in utero exposure to maternal DTG using the criteria below: * DTG-naïve: Infant born to a mother who did not receive DTG during the two weeks immediately prior to delivery. * DTG-exposed: Infant born to a mother who received at least one dose of DTG less than or equal to 72 hours prior to delivery. Across the two cohorts and two in utero exposure groups there were five study strata. Cohort 1: Two single DTG doses approximately seven days apart. * Cohort 1 Stratum 1A (DTG-naïve): DTG-naïve infants receiving 2 doses of DTG liquid suspension, with 1st dose at 0-5 days of life and 2nd dose at the 7 Days (+3 days) Post Initial Dose visit. * Cohort 1 Stratum 1B (DTG-exposed): DTG-exposed infants receiving 2 doses of DTG liquid suspension, with 1st dose at 2-5 days of life and 2nd dose at the 7 Days (+3 days) Post Initial Dose visit. * Cohort 1 Stratum 1C (DTG-naïve): DTG-naïve infants receiving 2 doses of DTG dispersible tablets, with 1st dose at 0-5 days of life and 2nd dose at the 7 Days (+3 days) Post Initial Dose visit. Cohort 2: Chronic DTG dosing through Week 4 or 6 visit based on the duration of local standard ARV prophylaxis. * Cohort 2 Stratum 2A (DTG-naïve): DTG-naïve infants receiving DTG 5 mg dispersible tablets every 48 hours from the Entry visit (0-5 days of life) through Day 13 (week 2) of life; then every 24 hours from Day 14 of life through the Week 4 or Week 6 visit based on the duration of local standard ARV prophylaxis. * Cohort 2 Stratum 2B (DTG-exposed): DTG-exposed infants receiving DTG 5 mg dispersible tablets every 48 hours from from the Entry visit (0-5 days of life) through Day 13 (week 2) of life; then every 24 hours from Day 14 of life through the Week 4 or Week 6 visit based on the duration of local standard ARV prophylaxis. A minimum of 12 and up to 36 M-I pairs (across strata) were planned to be enrolled in Cohort 1 to achieve a target of six evaluable infants in each stratum to provide PK and safety data to determine the starting DTG dose for each stratum in Cohort 2. A minimum of 24 and up to 72 mother-infant pairs (across both strata) were planned to be enrolled in Cohort 2 to achieve a target of 12 evaluable infants in both Strata 2A and 2B receiving the final proposed chronic dose of DTG. Breastfeeding and formula-feeding infants were eligible for both Cohorts 1 and 2. At least eight breastfeeding and eight formula-feeding infants were planned to be enrolled in Cohort 2 across both strata. Infant PK samples were collected as follows: Cohort 1: * Dose #1 (0-5 days of life) intensive PK sampling: prior to observed dose, 1-2 hours (±15 min) post-dose, 4-8 hours (±15 min) post-dose, 11-13 hours (±15 min) post-dose, 22-26 hours (±15 min) post-dose, 48-72 hours (±15 min) post-dose. * Dose #2 \[7 days post initial dose (+3 days)\] intensive PK sampling: prior to observed dose, 1-2 hours (±15 min) post-dose, 22-26 hours (±15 min) post-dose. Cohort 2: * First intensive PK sampling \[7 days post initial dose (+3 days)\]: prior to observed dose, 1-2 hours (±15 min) post-dose, 6-10 hours (±15 min) post-dose, 22-26 hours (±15 min) post-dose (collect PK sample prior to administration of next DTG dose if every 24-hour dosing interval used), prior to administration of the next dose (a sample at this time point should only be collected for Cohort 2 infants with DTG dose regimen administered more than every 24 hours, e.g., every 48 or 72 hours). * Second intensive PK sampling \[Week 4 (23-33 days of life)\]: prior to observed dose, 1-2 hours (±15 min) post-dose, 6-10 hours (±15 min) post-dose, 22-26 hours (±15 min) post-dose (collect PK sample prior to administration of next DTG dose if every 24-hour dosing interval used). Infant safety evaluations were done at: * Cohort 1: Entry, 7 days post initial dose, Week 4, Week 6, Week 16 * Cohort 2: Entry, 2 days post initial dose, 7 days post initial dose, Week 4, Week 6, Week 8, Week 12, Week 16. Infant tolerability evaluations were done at: * Cohort 1: Dose #1 (0-5 days of life), Dose #2 \[7 days post initial dose (+3 days)\] * Cohort 2: Entry, 2 days post initial dose, 7 days post initial dose (+3 days), Week 4, Week 6 Safety data included infant clinical data, laboratory test results and information on any infant deaths. Laboratory test results included evaluations specified in the protocol and results from the infant's clinical care. Adverse events were graded according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. Adverse events were defined as the occurrence of at least one grade 1 (mild), 2 (moderate), 3 (severe), 4 (potentially life-threatening), or 5 (death) adverse event, during the study follow-up. In addition, grading of axillary measured fever and plasma creatinine grading in this study followed protocol section 7.3.3. The study site's assessment of adverse event attribution to study drug was used. For the final analysis, all infants who received at least one dose of DTG are safety evaluable (same as in the Regulatory Submission Report). The protocol pharmacologists determined whether PK parameters can be estimated from the specimens collected, and as described in Protocol Section 3, these determinations were used to determine whether participants are PK evaluable.